Search

Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On

BIO ROUNDUP: BIG BUCKS FOR CALICO, DATA DUMPS & THE IPO WAVE ROLLS ON

If you're running a privately held biotech, the time to go public is now. Clinical data already in hand or not, biotechs have charged...

Lethal Prostate Cancer Treatment may Benefit from Combination Immunotherapy: Study

LETHAL PROSTATE CANCER TREATMENT MAY BENEFIT FROM COMBINATION IMMUNOTHERAPY: STUDY

A genetic subset of prostate cancer may benefit from the use of combination checkpoint immunotherapy.

 
 
 
Skyhawk Lands $100M from Funding & Celgene Pact for RNA-Targeted Drugs

SKYHAWK LANDS $100M FROM FUNDING & CELGENE PACT FOR RNA-TARGETED DRUGS

Almost exactly a year ago, a Boston-area cancer immunotherapy startup led by Bill Haney announced its first partnership , with Celgene....

Immune Profile for Successful Cancer Immunotherapy Identified

IMMUNE PROFILE FOR SUCCESSFUL CANCER IMMUNOTHERAPY IDENTIFIED

Multiple immune cell types must be present in tumors for 'checkpoint inhibitor' therapies to be effective.

 
 
 
Predicting the Success of Immunotherapy in Cancer Patients

PREDICTING THE SUCCESS OF IMMUNOTHERAPY IN CANCER PATIENTS

New study discovers a method for predicting the likelihood of treatment success in cancers.

 
 
 
Woman's late-stage breast cancer cured by breakthrough immunotherapy treatment  

WOMAN'S LATE-STAGE BREAST CANCER CURED BY BREAKTHROUGH IMMUNOTHERAPY TREATMENT  

A woman has been cured of her breast cancer by a revolutionary treatment that used supercharged versions of her own immunity cells...

ONCOSEC PRESENTS UPDATE ON PISCES/KEYNOTE-695 PHASE 2B REGISTRATION-DIRECTED CLINICAL TRIAL IN COMBINATION WITH MERCK'S KEYTRUDA® FOR METASTATIC MELANOMA AT THE ASCO 2018 ANNUAL MEETING

SAN DIEGO, June 4, 2018 /PRNewswire/ - OncoSec Medical Incorporated , a company developing intratumoral cancer immunotherapies, today...

 
 
 
Men with untreatable prostate cancer could halt its spread and live longer

MEN WITH UNTREATABLE PROSTATE CANCER COULD HALT ITS SPREAD AND LIVE LONGER

Men with otherwise untreatable prostate cancer could halt its spread and survive longer by undergoing immunotherapy treatment, a major...

 
 
 
New vaccine may keep patients alive 7 YEARS longer with the same cancer that killed Tessa Jowell

NEW VACCINE MAY KEEP PATIENTS ALIVE 7 YEARS LONGER WITH THE SAME CANCER THAT KILLED TESSA JOWELL

Scientists tested the DCVax-L injection, a form of immunotherapy, on more than 300 patients from the UK, US, Canada and Germany diagnosed...

An experimental cancer treatment cured this dog. Could it work for people?

AN EXPERIMENTAL CANCER TREATMENT CURED THIS DOG. COULD IT WORK FOR PEOPLE?

Our pets get sick in the same way we do. Finding cures for them is proving useful for us, too.

 
 
 
Eli Lilly Bolsters Cancer Drug Pipeline with $110M Deal for AurKa

ELI LILLY BOLSTERS CANCER DRUG PIPELINE WITH $110M DEAL FOR AURKA

Eli Lilly is pulling out its checkbook again to acquire another cancer drug developer, this time inking a deal for early-stage company...

 
 
 

PRECISION BIOSCIENCES TO PRESENT IN VIVO GENE THERAPY AND EX VIVO CANCER IMMUNOTHERAPY DATA AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY ANNUAL MEETING

Agenda Posted for Xconomy's What's Hot in Boston Biotech on May 16

AGENDA POSTED FOR XCONOMY'S WHAT'S HOT IN BOSTON BIOTECH ON MAY 16

Join Xconomy next month for our sixth installment of What's Hot in Boston Biotech on May 16 at the Broad Institute of MIT and Harvard....

 
 
 
Merck Immunotherapy Drug Shines In Lung Cancer Study

MERCK IMMUNOTHERAPY DRUG SHINES IN LUNG CANCER STUDY

Research finds that more than two-thirds of lung cancer patients who received Keytruda plus chemotherapy would be alive a year later,...

New immunotherapy drug becomes first ever to DOUBLE survival in lung cancer patients

NEW IMMUNOTHERAPY DRUG BECOMES FIRST EVER TO DOUBLE SURVIVAL IN LUNG CANCER PATIENTS

Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone...

 
 
 

FOR MORE LUNG CANCER PATIENTS, THE PROMISE OF NO CHEMO LOOMS LARGER

[Editor's note: Ben Fidler co-authored this report.] A decade from now, it's possible that immunotherapy will have made a big dent...

ONCOSEC PROVIDES HIGHLIGHTS FROM RESEARCH RECEPTION AT AACR ANNUAL MEETING 2018

SAN DIEGO, April 16, 2018 /PRNewswire/ - OncoSec Medical Incorporated , a company developing intratumoral cancer immunotherapies, today...